Kitov Pharma Receives Notice of Intention to Grant European Patent Covering the Use of NT-219 in Combination with EGFR Inhibitors

Kitov Pharma Receives Notice of Intention to Grant European

Patent Covering the Use of NT-219 in Combination with EGFR Inhibitors

Jan. 24, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage company advancing

first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced receipt from the European Patent

Office (EPO) of a Notice of Intention to Grant for its patent application entitled "Combinations of IRS/STAT3 Dual Modulators

and Anti-Cancer Agents for Treating Cancer." The patent, which expires in 2036, covers the treatment of NT-219, the

company's novel dual inhibitor of IRS 1/2 and STAT3, in combination with EGFR antibodies and inhibitors.

advancing NT-219 in combination with cetuximab, an EGFR antibody, as a second-line or third-line therapy for the treatment of recurrent

and metastatic squamous cell carcinoma of the Head & Neck Cancer (SCCHN). Kitov plans to initiate a phase 1/2 study in the

second quarter of 2020.

believe strongly in our rationale for combining NT-219 with cetuximab and we are very pleased with this new addition to our patent

estates in Europe," said Isaac Israel, Kitov's chief executive officer. "Cetuximab is currently the only

targeted FDA-approved treatment option for patients with a progressed disease following both prior platinum-based therapy and pembrolizumab.

NT-219 has the potential to prevent tumor resistance and re-sensitize tumors to the anti-cancer activity of EGFR inhibitors, making

this combination a very attractive drug candidate that will hopefully address the unmet medical need for recurrent and metastatic

Head and Neck cancer patients."

Pharma (Kitov Pharma Ltd.; NASDAQ/TASE: KTOV) is a clinical-stage company focusing on advancing first-in-class therapies to overcome

tumor immune evasion and drug resistance, to create successful long-lasting treatments for people with cancer. Kitov's oncology

pipeline includes NT-219 and CM-24. NT-219 is a small molecule targeting the novel cancer drug resistance pathways IRS1/2 and STAT3.

Kitov is currently advancing NT-219 in combination with cetuximab as a third-line or second-line treatment option for the treatment

of recurrent and metastatic squamous cell carcinoma of head & neck cancer (SCCHN). CM-24 is a monoclonal antibody blocking

CEACAM1, a novel immune checkpoint that supports tumor immune evasion and survival through multiple pathways. Kitov will advance

CM-24 as a combination therapy with anti-PD1 checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC). Kitov

has entered into a clinical collaboration agreement with Bristol Myers Squibb (NYSE:BMY) for the planned Phase 1/2 clinical trials

to evaluate the combination of CM-24 with the PD-1 inhibitor nivolumab (Opdivo ). Kitov is also the owner of Consensi ,

a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension

which was approved by the FDA for marketing in the U.S in May 2018 and is expected to be launched in the U.S. during 2020 by its

partner Coeptis Pharmaceuticals. Kitov has also partnered to commercialize Consensi in China and South Korea. The company is headquartered

in Tel Aviv, Israel. For more information, please visit http://www.kitovpharma.com.

Statements and Kitov's Safe Harbor Statement

statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements

within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking

statements include, but are not limited to, statements that are not statements of historical fact, and may be identified by words

such as "believe", "expect", "intend", "plan", "may", "should",

"could", "might", "seek", "target", "will", "project",

"forecast", "continue" or "anticipate" or their negatives or variations of these words or other

comparable words or by the fact that these statements do not relate strictly to historical matters. You should not place undue

reliance on these forward-looking statements, which are not guarantees of future performance. Forward-looking statements reflect

our current views, expectations, beliefs or intentions with respect to future events, and are subject to a number of assumptions,

involve known and unknown risks, many of which are beyond our control, as well as uncertainties and other factors that may cause

our actual results, performance or achievements to be significantly different from any future results, performance or achievements

expressed or implied by the forward-looking statements. Important factors that could cause or contribute to such differences include,

among others, risks relating to: different results from the expected benefits, synergies and costs of the acquisition of FameWave

by Kitov; management plans relating to the transaction; the plans, strategies and objectives of management for future operations;

product development for NT219 and CM-24; the potential future financial impact of the transaction; and any assumptions underlying

any of the foregoing; the process by which early stage therapeutic candidates such as NT219 and CM-24 could potentially lead

to an approved drug product is long and subject to highly significant risks, particularly with respect to a joint development collaboration;

the fact that drug development and commercialization involves a lengthy and expensive process with uncertain outcomes; our ability

to successfully develop and commercialize our pharmaceutical products; the expense, length, progress and results of any clinical

trials; the lack of sufficient funding to finance the clinical trials; the impact of any changes in regulation and legislation

that could affect the pharmaceutical industry; the difficulty in receiving the regulatory approvals necessary in order to commercialize

our products; the difficulty of predicting actions of the U.S. Food and Drug Administration or any other applicable regulator of

pharmaceutical products; the regulatory environment and changes in the health policies and regimes in the countries in which we

operate; the uncertainty surrounding the actual market reception to our pharmaceutical products once cleared for marketing in a

particular market; the introduction of competing products; patents attained by competitors; dependence on the effectiveness of

our patents and other protections for innovative products; our ability to obtain, maintain and defend issued patents with protective

claims; the commencement of any patent interference or infringement action; our ability to prevail, obtain a favorable decision

or recover damages in any such action; and the exposure to litigation, including patent litigation, and/or regulatory actions,

and other factors that are discussed in our in our Annual Report on Form 20-F for the year ended December 31, 2018 and in our other

filings with the SEC, including our cautionary discussion of risks and uncertainties under Risk Factors' in our Registration

Statements and Annual Reports. These are factors that we believe could cause our actual results to differ materially from expected

results. Other factors besides those we have listed could also adversely affect us. Any forward-looking statement in this press

release speaks only as of the date which it is made. We disclaim any intention or obligation to publicly update or revise any forward-looking

statement, or other information contained herein, whether as a result of new information, future events or otherwise, except as

required by applicable law. You are advised, however, to consult any additional disclosures we make in our reports to the SEC,

which are available on the SEC's website, http://www.sec.gov

Deputy CEO & Chief Financial Officer

+972-3-933-3121 ext. #105